A4250 + CRC (A3384) + Questran + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Orphan Cholestatic Liver Diseases
Conditions
Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis, Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome
Trial Timeline
Jul 1, 2013 → May 1, 2014
NCT ID
NCT02963077About A4250 + CRC (A3384) + Questran + Placebo
A4250 + CRC (A3384) + Questran + Placebo is a phase 1 stage product being developed by Ipsen for Orphan Cholestatic Liver Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT02963077. Target conditions include Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis, Progressive Familial Intrahepatic Cholestasis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02963077 | Phase 1 | Completed |
Competing Products
2 competing products in Orphan Cholestatic Liver Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Caffeine + Dextromethorphan + Enzalutamide + Enzalutamide Placebo to Match (PTM) | Astellas Pharma | Phase 1 | 33 |
| 3 mg [14C]-A4250 capsule | Ipsen | Phase 1 | 30 |